Table 3.
Summary of statistical tests
| Stage | Test | First Group (Overexpression of GSC Marker Candidates Expected) | Second Group | DATA ORIGIN | |||
|---|---|---|---|---|---|---|---|
| Tissue/Cells | N | Tissue/Cells | N | Database | Dataset | ||
| Selection | 1 | GB | 77 | Non-malignant brain tissue | 23 | GEO | GSE4290/GDS1962 |
| 2 | GB | 77 | Grade II glioma | 45 | GEO | GSE4290/GDS1962 | |
| 3 | GB | 77 | oligodendroglioma | 50 | GEO | GSE4290/GDS1962 | |
| 4 | GSCL | 27 | GB tumor tissue | 12 | GEO | GSE23806/GDS3885 | |
| 5 | GSCL | 27 | Conventional GB cell lines | 32 | GEO | GSE23806/GDS3885 | |
| 6 | neurospheres | 17 | GB tumor tissue | 12 | GEO | GSE23806/GDS3885 | |
| 7 | neurospheres | 17 | Conventional GB cell lines | 32 | GEO | GSE23806/GDS3885 | |
| 8 | GB | 143 | Grade II glioma | 110 | GLIOMASdb | / | |
| Validation | v1-1 | GB | 228 | Non-malignant brain tissue | 28 | ArrayExpress | E-GEOD-68848 |
| v2-1 | GB | 24 | Grade II glioma | 63 | ArrayExpress | E-GEOD-52009 | |
| v2-2 | GB | 134 | Grade II glioma | 99 | ArrayExpress | E-GEOD-68848 | |
| v2-3 | GB | 159 | Grade II glioma | 24 | ArrayExpress | E-GEOD-16011 | |
| v3-1 | GB | 59 | oligodendroglioma | 11 | GEO | GSE4412/GDS1975 | |
| v3-2 | GB | 59 | oligodendroglioma | 11 | GEO | GSE4412/GDS1976 | |
| v3-3 | GB | 24 | oligodendroglioma | 13 | ArrayExpress | E-GEOD-52009 | |
| v3-4 | GB | 228 | oligodendroglioma | 67 | ArrayExpress | E-GEOD-68848 | |
| v3-5 | GB | 159 | oligodendroglioma | 52 | ArrayExpress | E-GEOD-16011 | |
| v4-1 | GSCL | 28 | GB tumor tissue | 17 | ArrayExpress | E-GEOD-4536 | |
| v5-1 | GSCL | 28 | Conventional GB cell lines | 26 | ArrayExpress | E-GEOD-4536 | |
| v6-1 | neurospheres | 9 | GB tumor tissue | 9 | ArrayExpress | E-GEOD-74571 | |
| v7-1 | neurospheres | 9 | Conventional GB cell lines | 10 | ArrayExpress | E-GEOD-74571 | |
N = number of samples, GB = glioblastoma.